Shenzhen Kangtai Biological Products Co., Ltd. is a listed enterprise integrating research, development, production and sales of biological products, stock code 300601. Headquartered in Shenzhen, the company has R&D centers and industrial bases in Shenzhen and Beijing. It is one of the major hepatitis B vaccine manufacturers in China.
The company's main business is the development, production and sales of human vaccines. The product categories cover Class I and Class II vaccines. The main products are recombinant hepatitis B vaccine (Saccharomyces cerevisiae), Haemophilus influenzae type b conjugate vaccine, and measles and rubella. Live attenuated vaccine, cell-free white-breaking Haemophilus influenzae type b combined vaccine and other products.
Since its establishment in 1992, BioKangtai has undertaken a number of national, provincial and municipal key scientific research projects and technology development tasks, and has possessed core technologies such as polyvalent vaccines, genetic engineering vaccines and other new technology R&D and industrialization core competitiveness. The company has 8 research and development carriers such as academician expert workstations, and its products cover more than 3,130 provinces, municipalities and autonomous regions. Among them, the self-developed cell-free whitebait b-type Haemophilus influenzae combined vaccine is the domestically-innovated “quadruple vaccine”, and the 60-microg hepatitis B vaccine specifically targeting unresponsive people has the “National Key New Product” title.
Through more than 20 years of unremitting efforts, BioKangtai has become a national-level high-tech enterprise with a full range of R&D products, a rich product line, and obvious technological advantages. It has played an important role in the national plan for the immunization front. In the hepatitis B vaccine alone, BioKangtai has produced and sold 1 billion doses, helped more than 300 million people to rid the hepatitis B virus, and reduced public health expenditure by more than 160 billion yuan, which has extremely important economic and social value.
After the outbreak of the COVID-19 in early 2020, BioKangtai has started R&D and industrialization of the COVID-19 vaccine. Also it carried out the research and development of several technical routes, such as the COVID-19 inactivated vaccine (Vero cell) and the adenovirus vector COVID-19 vaccine.The COVID-19 inactivated vaccine (Vero cell) independently developed by BioKangtai has been approved for clinical trial by the National Medical Products Administration and became the first coronavirus vaccine officially entering the clinical trial in Guangdong Province.
The first phase of the COVID-19 inactivated vaccine production workshop constructed in Nanshan District of Shenzhen has been completed. It is expected to have an annual production capacity of 100 million doses by the end of December this year. BioKangtai and AstraZeneca's adenovirus vector COVID-19 vaccine is the first international anti epidemic cooperation project in Guangdong Province. The two sides jointly promote the clinical development, production and commercialization of the adenovirus vector COVID-19 vaccine AZD1222, which is jointly developed by AstraZeneca and Oxford University, in the Chinese mainland market. The design capacity of the vaccine reaches 200 million doses / year.